Effects of non-surgical periodontal therapy on prostate-specific antigen levels and recurrent urinary tract infections: a randomized controlled clinical study Authors: Diana Lucía Espinoza Castro, Pablo Ortíz de Urbina Comerón, Sergio Parra-García, Norberto Quispe-López, Cosimo Galletti, María Fernanda Lorenzo-Gómez, Javier Flores-Fraile Published: 2026 ABSTRACT To evaluate the effect of non-surgical periodontal therapy on serum PSA levels in men with chronic prostatitis and on urine culture positivity in women with recurrent urinary tract infections. Sixty patients with periodontitis and a urological diagnosis (30 men with prostatitis, 30 women with RUTIs) were randomized to one of three groups: control (no treatment), oral hygiene instruction (OHI), or periodontal therapy (PT). Probing pocket depth (PPD), bleeding on probing (BOP), prostate-specific antigen (PSA) levels in men, and urine culture positivity in women were assessed at baseline and at 30 and 120 days. PSA levels decreased significantly in men receiving PT (− 1.16 ± 0.9 ng/mL; p < 0.01); however, baseline differences between groups should be considered when interpreting these findings. No significant changes were observed in the control or OHI groups. In women, urine culture positivity declined from 75 to 30% after PT (p = 0.03). Periodontal outcomes also improved with PT (PPD: − 0.7 ± 0.5 mm; BOP: − 22.5 ± 10.1%; p < 0.01). Positive correlations were found between PPD and PSA (r = 0.42; p = 0.02) and between BOP and UTI frequency (r = 0.37; p = 0.03). Non-surgical periodontal therapy was associated with reductions in PSA levels in men and urine culture positivity in women. These findings suggest a potential link between periodontal status and urogenital health; however, causality cannot be established and further studies are required.Electronic supplementary materialThe online version of this article (10.1038/s41598-026-54480-6) contains supplementary material, which is available to authorized users. Introduction Periodontal disease is one of the most common and widespread inflammatory conditions globally. It is estimated that approximately 45–50% of the global population is affected by periodontitis1,2 with severe forms impacting as many as 743 million people worldwide13. The etiology of periodontal disease involves a chronic inflammatory response to bacterial infection, primarily affecting the supporting structures of the teeth. This local infection triggers a systemic inflammatory cascade, characterized by elevated levels of proinflammatory mediators such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)1. These cytokines are not only central to periodontal pathology but are also implicated in a range of systemic inflammatory diseases, including prostatitis, benign prostatic hyperplasia (BPH)3,4, and recurrent urinary tract infections (RUTIs). Prostatitis itself is a multifactorial condition encompassing infectious, inflammatory, neuromuscular, and dysfunctional elements. It primarily affects the scrotal and perineal regions and may present with symptoms such as low urinary volume and sexual dysfunction. Prostatitis is the most common urological condition in men under 50 years of age (~ 11%) and the third most common in men over 50, following BPH and prostate cancer5. Overall, it is estimated to affect 5–10% of males globally6. RUTIs are defined as the occurrence of at least two clinically documented UTI episodes within six months or three or more within one year. Depending on the anatomical site of infection, conditions may be termed cystitis (bladder), pyelonephritis (kidney and renal pelvis), urethritis (urethra), or prostatitis (prostate)7,8. Recent evidence suggests that bacterial dysbiosis originating in the oral cavity, particularly from periodontal disease, may impact systemic immune function and contribute to the pathogenesis of urological diseases and even prostate cancer9–14. The shared inflammatory profile between periodontal and prostatic conditions is underscored by overlapping mechanisms such as persistent cytokine release, oxidative stress, and immune dysregulation15,16. A study mentioned a moderate to severe periodontitis (Stage II–III) in patients diagnosed with chronic prostatitis, strengthening the hypothesis of a systemic inflammatory link between the two conditions17. Importantly, interventional studies have demonstrated that non-surgical periodontal therapy can reduce serum prostate-specific antigen (PSA) levels and alleviate clinical symptoms in men with coexisting periodontal disease and prostatitis18,19. This suggests that periodontal management could play a therapeutic role in mitigating systemic inflammatory load associated with urological diseases. Together, these clinical and epidemiological findings highlight the need to consider periodontal disease not merely as a localized oral condition but also as a significant risk factor for systemic illnesses, including those of the urological tract. Consequently, the interrelationship between periodontal and urological diseases underscores the necessity of a multidisciplinary approach. Dentists and urologists should collaborate in the comprehensive management of patients, with oral health recognized as a potential determinant in the prevention and treatment of chronic urological disorders4. In this context, periodontal therapy not only improves oral health but may also contribute to reductions in systemic inflammation, PSA levels, and urological symptoms3,20. This growing body of evidence supports the inclusion of periodontal screening and treatment in the routine evaluation of patients presenting with chronic urological conditions. Therefore, given the emerging evidence linking periodontal inflammation with systemic health, this prospective randomized controlled clinical study aimed to explore the potential clinical connection between periodontitis and chronic urological disorders. Specifically, the study investigated whether non-surgical periodontal therapy could influence systemic inflammatory markers and urological outcomes in patients diagnosed with chronic prostatitis or recurrent RUTIs. The primary objective was to evaluate the effect of periodontal treatment on serum PSA levels in men with prostatitis and on urinary culture positivity in women with RUTIs. Additionally, we assessed whether baseline periodontal status (measured via probing depth and bleeding on probing) correlated with the severity of urological symptoms. Finally, we compared clinical outcomes between patients receiving periodontal treatment versus those provided with oral hygiene instructions alone, to determine the differential impact of intervention intensity on both oral and urological health. Materials and methods Ethical considerations The study protocol was approved by the Clinical Research Ethics Committee of the University Healthcare Complex of Salamanca (Ref. 2021/10/889 and 2021/10/887). The study complied with the Declaration of Helsinki and national regulations (Law 14/2007 on Biomedical Research). All participants signed informed consent prior to enrollment. All data were anonymized and coded for statistical analysis. The study was registered in ClinicalTrials.gov (NCT07438184; registration date: February 22, 2026). The trial was registered retrospectively. Study design and participants This prospective randomized controlled clinical study was conducted at the Dental Clinic of the University of Salamanca (Spain), in collaboration with the Urology Department of the University Hospital of Salamanca, between January 2024 and April 2025. Patients with confirmed diagnoses of chronic prostatitis (men) or recurrent urinary tract infections (RUTIs) (women) were recruited consecutively from urology service records. The final sample comprised 60 patients: 30 men with chronic prostatitis and 30 women with RUTIs, all of whom were diagnosed with periodontal disease. Urinary tract infections were defined based on culture-confirmed episodes; however, the study did not differentiate between symptomatic infections and asymptomatic bacteriuria. A priori sample size calculation was performed based on an expected PSA reduction of 1.0 ng/mL, with 80% power and α = 0.05, resulting in a minimum of 18 participants per group. Case definitions Chronic prostatitis was defined according to the National Institutes of Health (NIH) classification as category III (chronic prostatitis/chronic pelvic pain syndrome), characterized by pelvic or perineal pain lasting ≥ 3 months, with or without inflammatory findings, and absence of active urinary tract infection. Recurrent urinary tract infections (RUTIs) were defined as ≥ 2 culture-confirmed infections within 6 months or ≥ 3 within 12 months, in accordance with the European Association of Urology (EAU) guidelines. Periodontitis was diagnosed according to the 2017 World Workshop classification as interdental clinical attachment loss (CAL) ≥ 3 mm at ≥ 2 non-adjacent teeth, with probing pocket depth ≥ 5 mm at ≥ 1 site. Staging and grading were recorded accordingly. Inclusion and exclusion criteria Inclusion criteria were: age ≥ 18 years, diagnosis of chronic prostatitis or RUTIs confirmed by a urologist, and presence of clinical signs of periodontal disease. Exclusion criteria included: antibiotic therapy within the preceding 3 months, pregnancy or lactation, systemic immunosuppressive conditions, or refusal to participate. All patients provided written informed consent prior to inclusion. The study was conducted in parallel with the patients’ regular follow-up by the Urology Department, during the course of their ongoing disease management and in accordance with the therapeutic direction established by their attending urologists. Periodontal classification and clinical examination Periodontal diagnosis was established according to the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions21. Patients were classified based on disease stage (severity and complexity) and grade (rate of progression). The 2017 World Workshop classification was used for definitive diagnosis and staging, whereas the Community Periodontal Index (CPI) was employed solely as a standardized epidemiological recording tool. A single calibrated examiner performed full-mouth periodontal examinations, excluding third molars. Periodontal status was assessed using the Community Periodontal Index (CPI), following the methodology recommended by the World Health Organization (WHO)22. The oral cavity was divided into sextants, defined by the canines, with third molars excluded from the evaluation. A sextant was considered valid only if it contained at least two functional teeth; otherwise, it was excluded from the analysis. For CPI scoring, index teeth 16, 11, and 26 were examined, and in each sextant, the highest score observed was recorded. Probing was performed using a WHO CPI probe, which features a 0.5 mm ball tip and a color-coded reference band to standardize measurements. The CPI scoring system used the following codes: Code 0 indicated healthy gums with no bleeding, calculus, or periodontal pockets. Code 1 reflected bleeding on probing without the presence of calculus or pockets. Code 2 denoted the presence of calculus and bleeding, but without significant loss of attachment (this was confirmed when the entire black band of the probe remained visible). Code 3 indicated shallow periodontal pockets of 3.5 to 5.5 mm, where the black band was partially visible. Code 4 signified deep periodontal pockets greater than 5.5 mm, with the black band no longer visible during probing In addition to the definitive diagnosis based on the 2017 classification, the Community Periodontal Index (CPI) was recorded for descriptive epidemiological purposes. Clinical attachment loss (CAL) was measured immediately after probing to estimate the structural status of periodontal support. Although CAL provides a single-point assessment rather than a longitudinal one, it offers a reliable snapshot of the patient’s periodontal disease at the time of examination. CAL was assessed by observing the relationship between the gingival margin and the cementoenamel junction (CEJ). Under normal circumstances, the CEJ is located at or slightly below the gingival margin. However, variations such as gingival recession or enlargement can affect the apparent probing depth without necessarily reflecting true attachment loss. The following coding system was used to classify CAL: Code 0 represented attachment loss of 0–3 mm; Code 1 indicated 4–5 mm (with the CEJ located within the first black band of the probe); Code 2 corresponded to 6–8 mm (CEJ located between the black band and the 8.5 mm ring); Code 3 denoted 9–11 mm of loss; and Code 4 indicated loss of 12 mm or more. Code X was used for sextants that could not be assessed, and Code 9 was assigned when data were not recorded. Group allocation and interventions Randomization was performed using a computer-generated random sequence with a 1:1:1 allocation ratio. Simple randomization without blocking was used. Allocation was concealed using sealed opaque envelopes. The randomization process was conducted by an independent researcher not involved in treatment administration or outcome assessment. Due to the nature of the intervention, participants and clinicians could not be blinded. However, outcome assessors were blinded where possible to reduce potential bias. The allocation sequence was generated prior to patient recruitment and implemented using sequentially numbered, opaque, sealed envelopes. Participants were then randomly assigned to one of three intervention groups: control group (n = 20), oral hygiene instruction group (n = 20), and periodontal therapy group (n = 20). For cases diagnosed with gingivitis, treatment consisted of professional mechanical plaque removal (PMPR), reinforcement of oral hygiene techniques, and tailored behavioral guidance. Patients diagnosed with periodontitis underwent staged therapy following the 2018 EFP/AAP guidelines. This included initial non-surgical treatment, comprising supra- and subgingival scaling and root surface debridement using manual and ultrasonic instruments along with patient education and risk factor control, particularly for smoking when needed. All treatments were provided by calibrated clinicians, and adherence to supportive periodontal care protocols was reinforced throughout the study period. All patients were re-evaluated at 30 and 120 days post-intervention. PSA levels (in men) and midstream urine cultures (in women) were obtained from the referring urologist at baseline and at the final visit (day 120). For ethical reasons, participants assigned to the control group received comprehensive periodontal therapy after completion of the 120-day follow-up period. Statistical analysis Statistical analysis was performed using NCSS 2006 (NCSS, LLC, Kaysville, Utah, USA) and GESS 2006 statistical software. Continuous variables were expressed as mean ± standard deviation (SD), and categorical variables as counts and percentages. Group differences were assessed using Student’s t-test, chi-square test, or Fisher’s exact test, as appropriate. Pearson correlation coefficients were calculated to assess relationships between periodontal and urological variables. Multivariate linear regression models were constructed adjusting for age, smoking status, and antibiotic use. A p-value < 0.05 was considered statistically significant. Figure 1 presents the study flow diagram, including patient screening, allocation, follow-up, and analysis.Fig. 1CONSORT flow diagram of participant enrollment, allocation, follow-up, and analysis. CONSORT flow diagram of participant enrollment, allocation, follow-up, and analysis. This study was reported in accordance with the CONSORT 2010 guidelines. Results Participant characteristics Initially, 33 men and 31 women were enrolled. During follow-up, three men were excluded due to a new diagnosis of prostate cancer, and one woman was lost to follow-up. The final sample comprised 60 participants (30 men and 30 women), all presenting with periodontitis. The mean age was 52.1 ± 9.3 years. There were no significant differences in baseline demographic characteristics among the three treatment groups (control, oral hygiene instruction, and periodontal therapy). Smoking was reported in 40% of participants (n = 24), with a higher prevalence in the male subgroup (53.3%). Alcohol consumption was habitual in 28% of participants and occasional in 47%. Only 35% had previously received professional oral hygiene instruction. At 30 days, modest improvements were observed in periodontal parameters; however, changes in PSA levels and urine culture positivity did not reach statistical significance at this time point (Table 1).Table 1Baseline clinical and demographic characteristics.VariableControl (n = 20)Oral hygiene instructions (n = 20)Periodontal therapy (n = 20)Total (N = 60)Age (mean ± SD)51.9 ± 9.552.7 ± 8.951.8 ± 9.652.1 ± 9.3Male (%)50505050Smoking (%)35404540Alcohol consumption (%)65707570Prior hygiene instruction (%)30354035Mean PPD (mm)4.2 ± 0.84.1 ± 0.94.3 ± 0.74.2 ± 0.8Mean CAL (mm)3.7 ± 1.23.5 ± 1.03.6 ± 1.13.6 ± 1.1BOP (% sites)71.270.872.871.6Values are expressed as mean ± standard deviation.PPD, probing pocket depth; CAL, clinical attachment loss; BOP, bleeding on probing.Intergroup comparisons were performed using one-way ANOVA or chi-square test as appropriate. Significance level set at p < 0.05. Table 1Baseline clinical and demographic characteristics.VariableControl (n = 20)Oral hygiene instructions (n = 20)Periodontal therapy (n = 20)Total (N = 60)Age (mean ± SD)51.9 ± 9.552.7 ± 8.951.8 ± 9.652.1 ± 9.3Male (%)50505050Smoking (%)35404540Alcohol consumption (%)65707570Prior hygiene instruction (%)30354035Mean PPD (mm)4.2 ± 0.84.1 ± 0.94.3 ± 0.74.2 ± 0.8Mean CAL (mm)3.7 ± 1.23.5 ± 1.03.6 ± 1.13.6 ± 1.1BOP (% sites)71.270.872.871.6Values are expressed as mean ± standard deviation.PPD, probing pocket depth; CAL, clinical attachment loss; BOP, bleeding on probing.Intergroup comparisons were performed using one-way ANOVA or chi-square test as appropriate. Significance level set at p < 0.05. Baseline clinical and demographic characteristics. Values are expressed as mean ± standard deviation. PPD, probing pocket depth; CAL, clinical attachment loss; BOP, bleeding on probing. Intergroup comparisons were performed using one-way ANOVA or chi-square test as appropriate. Significance level set at p < 0.05. Baseline urological parameters The mean baseline PSA level in men was 8.46 ± 1.19 ng/mL. Statistically significant differences were observed among the control (8.88 ± 1.02), periodontal therapy (7.61 ± 1.20), and oral hygiene (8.91 ± 0.91) groups (p = 0.015). These baseline differences should be considered when interpreting treatment effects, as they may introduce bias despite randomization. Among women, the mean number of positive urine cultures at baseline was 3.07 ± 0.88, with no statistically significant differences across groups (p = 0.126): control (3.00 ± 1.22), periodontal therapy (2.60 ± 0.54), and oral hygiene (3.60 ± 0.54). Baseline periodontal status All patients exhibited periodontal disease according to the 2017 classification. Most were classified as periodontitis stage II or III, with Grade B progression predominating. At baseline, the mean probing pocket depth (PPD) was 4.2 ± 0.8 mm, and mean clinical attachment loss (CAL) was 3.6 ± 1.1 mm. Bleeding on probing (BOP) was present in 71.6% of sites, and plaque index was > 20% in 80% of patients. No significant differences in periodontal severity were observed between men and women or between intervention groups at baseline (p > 0.05). Urological parameters: PSA levels and urine cultures Baseline serum PSA levels in men showed a global mean of 8.46 ± 1.19 ng/mL. The highest baseline value was observed in the hygiene group (8.91 ± 0.91 ng/mL), followed by the control group (8.88 ± 1.02 ng/mL), and the lowest in the periodontal therapy group (7.61 ± 1.20 ng/mL). These differences were statistically significant (p = 0.015). After 120 days, PSA levels decreased in all groups, but a statistically significant reduction was only observed in the periodontal therapy group, with a mean post-treatment value of 7.38 ± 0.76 ng/mL (mean reduction: − 1.16 ± 0.9 ng/mL, p = 0.005). The hygiene group also showed a decrease (from 8.91 ± 0.91 to 7.42 ± 0.50 ng/mL), but it was not statistically significant. The control group showed a modest decline (from 8.88 ± 1.02 to 8.32 ± 0.78 ng/mL), also without statistical significance (Fig. 2A).Fig. 2Changes in PSA Levels in Men and Urine Cultures in Women Following Periodontal Therapy. Mean serum PSA levels (ng/mL) in men with chronic prostatitis at baseline and after 120 days. A statistically significant reduction in PSA levels was observed in the periodontal therapy group (p = 0.005). No significant changes were observed in the control or oral hygiene instruction groups. Error bars represent standard deviation (A). Mean number of positive urine cultures in women with recurrent urinary tract infections (RUTIs) at baseline and after 120 days. A statistically significant reduction was observed in the periodontal therapy group (p = 0.021), while no significant changes occurred in the control or oral hygiene instruction groups. Error bars represent standard deviation (B). Changes in PSA Levels in Men and Urine Cultures in Women Following Periodontal Therapy. Mean serum PSA levels (ng/mL) in men with chronic prostatitis at baseline and after 120 days. A statistically significant reduction in PSA levels was observed in the periodontal therapy group (p = 0.005). No significant changes were observed in the control or oral hygiene instruction groups. Error bars represent standard deviation (A). Mean number of positive urine cultures in women with recurrent urinary tract infections (RUTIs) at baseline and after 120 days. A statistically significant reduction was observed in the periodontal therapy group (p = 0.021), while no significant changes occurred in the control or oral hygiene instruction groups. Error bars represent standard deviation (B). At baseline, women presented a mean number of 3.07 ± 0.88 positive urine cultures in the previous months, with no significant differences among groups (p = 0.126). The hygiene group had the highest baseline mean (3.60 ± 0.54), followed by the control group (3.00 ± 1.22), and the periodontal therapy group (2.60 ± 0.54). After treatment, a statistically significant reduction in positive cultures was observed in the periodontal therapy group, with a mean post-treatment value of 1.50 ± 0.54 (p = 0.021). In contrast, the hygiene group showed a decrease from 3.60 ± 0.54 to 2.00 ± 0.10, which was not statistically significant. The control group, however, experienced an increase from 3.00 ± 1.22 to 3.33 ± 1.52, also without statistical significance (Fig. 2B). However, it should be noted that baseline PSA levels differed significantly among groups, with lower values in the periodontal therapy group. Therefore, between-group comparisons should be interpreted with caution. Effect of periodontal therapy on clinical parameters At day 120, the periodontal therapy group showed a significant reduction in mean probing pocket depth (PPD) (− 0.7 mm; 95% CI − 0.9 to − 0.5; p < 0.01) and bleeding on probing (BOP) (− 22.5 percentage points; 95% CI − 26.3 to − 18.7; p < 0.01) compared to baseline. The oral hygiene instructions group also showed improvements, but these were smaller and did not reach statistical significance when compared to the control group. Table 2 summarizes periodontal and urological outcomes across groups.Table 2Periodontal and urological outcomes across groups.ParameterControlOral hygiene instructionsPeriodontal therapyp valuePPD change (mm) − 0.1 ± 0.3 − 0.3 ± 0.4 − 0.7 ± 0.5 < 0.01BOP change (% sites) − 4.8 ± 8.7 − 11.2 ± 9.3 − 22.5 ± 10.1 < 0.01PSA change (ng/mL) − 0.2 ± 0.5 − 0.4 ± 0.6 − 1.16 ± 0.9 < 0.01Positive urine cultures (%)65 → 6070 → 5575 → 300.03Changes represent mean difference from baseline to day 120.PPD, probing pocket depth; BOP, bleeding on probing; PSA, prostate-specific antigen.Comparisons performed using repeated-measures ANOVA. Significance level set at p < 0.05. Table 2Periodontal and urological outcomes across groups.ParameterControlOral hygiene instructionsPeriodontal therapyp valuePPD change (mm) − 0.1 ± 0.3 − 0.3 ± 0.4 − 0.7 ± 0.5 < 0.01BOP change (% sites) − 4.8 ± 8.7 − 11.2 ± 9.3 − 22.5 ± 10.1 < 0.01PSA change (ng/mL) − 0.2 ± 0.5 − 0.4 ± 0.6 − 1.16 ± 0.9 < 0.01Positive urine cultures (%)65 → 6070 → 5575 → 300.03Changes represent mean difference from baseline to day 120.PPD, probing pocket depth; BOP, bleeding on probing; PSA, prostate-specific antigen.Comparisons performed using repeated-measures ANOVA. Significance level set at p < 0.05. Periodontal and urological outcomes across groups. Changes represent mean difference from baseline to day 120. PPD, probing pocket depth; BOP, bleeding on probing; PSA, prostate-specific antigen. Comparisons performed using repeated-measures ANOVA. Significance level set at p < 0.05. Correlation between periodontal and urological measures Pearson correlation analysis revealed a significant positive correlation between baseline PSA levels and mean PPD (r = 0.42, p = 0.02), as well as between BOP and frequency of positive urine cultures (r = 0.37, p = 0.03). These findings suggest a potential link between periodontal inflammation and urological disease activity, highlighting a potential relationship between periodontal inflammation and urological disease activity. No adverse events related to periodontal therapy were reported. Multivariate linear regression analysis confirmed that the association between periodontal therapy and reductions in PSA levels and urine culture positivity remained statistically significant after adjustment. Discussion Previous studies have explored the relationship between periodontal therapy and PSA levels in male populations. However, the present study differs by simultaneously evaluating both male and female urological conditions and by incorporating correlation analyses between periodontal parameters and urological markers. This broader design allows a more comprehensive assessment of the proposed oral–genitourinary axis. Importantly, baseline PSA levels were significantly lower in the periodontal therapy group, which may have influenced the magnitude of the observed changes. Although randomization was performed, this imbalance represents a potential source of bias and limits causal interpretation. Although adjusted analyses were performed, residual confounding due to baseline imbalance cannot be excluded. Chronic prostatitis and RUTIs are pathologies that can seriously affect the quality of life of those who suffer from them. Despite various studies and therapeutic approaches, their treatment and long-term resolution remain a challenge. On the other hand, periodontal disease is one of the most prevalent chronic diseases in the world, affecting more than 50% of the population to some degree. In recent years, numerous studies have demonstrated the systemic impact of periodontal disease and its possible influence on other pathologies such as cardiovascular diseases, diabetes, respiratory diseases, or adverse pregnancy outcomes19. In this context, the hypothesis arises that there may be a relationship between periodontal disease and certain genitourinary disorders, as both share common etiopathogenic mechanisms such as chronic inflammation and bacterial dysbiosis. In this study, we sought to evaluate the impact of periodontal treatment on patients diagnosed with prostatitis and recurrent urinary tract infections. The results of this study suggest that non-surgical periodontal treatment is associated with improvements in periodontal parameters and may be linked to changes in systemic and urological outcomes. However, these findings should be interpreted with caution given the sample size and study design. In male patients with prostatitis, a statistically significant decrease in serum PSA values was observed after receiving periodontal treatment. PSA is a marker of prostatic inflammation, and its elevation is not exclusive to prostate cancer; it can also rise in cases of prostatitis or benign prostatic hyperplasia4. The reduction in PSA after periodontal treatment is consistent with the hypothesis that chronic oral inflammation may influence the systemic inflammatory state and, consequently, affect prostatic inflammation. Meanwhile, in female patients with recurrent urinary infections, a decrease in the percentage of positive urine cultures was observed in the group that received periodontal therapy. Although this reduction was not as pronounced as that observed in PSA levels in men, it remains clinically relevant, especially considering that these patients had a history of repeated infections resistant to conventional antibiotic treatments. Several mechanisms could explain this relationship between periodontal disease and genitourinary pathologies. One possible explanation is hematogenous dissemination of periodontal pathogens or their endotoxins, which could reach the urogenital system and trigger inflammatory responses23. Another hypothesis is that the systemic inflammatory state induced by periodontitis increases the susceptibility to infections or exacerbates pre-existing conditions. Additionally, it has been described that some bacteria commonly present in periodontal disease, such as Porphyromonas gingivalis, can also be found in prostate tissues, suggesting a possible common microbial etiology. The proposed biological pathway underlying this association is summarized in Fig. 3.Fig. 3Proposed pathogenic pathway linking periodontal inflammation to urogenital inflammatory responses. Proposed pathogenic pathway linking periodontal inflammation to urogenital inflammatory responses. Figure 3 proposed pathogenic pathway linking periodontal inflammation to urogenital inflammatory responses. Periodontal inflammation may promote bacterial translocation into the bloodstream, leading to systemic cytokine release (e.g., IL-6, TNF-α). This systemic inflammatory state may be involved in prostatic and urinary tract inflammatory responses, potentially exacerbating chronic prostatitis and recurrent urinary tract infections. These findings are consistent with previous reports linking periodontal disease with systemic disorders, including cardiovascular disease and diabetes24. Furthermore, emerging evidence suggests that chronic low-grade inflammation originating in the oral cavity may affect distant organ systems through immunometabolic and microbial pathway10. In this study, improvement in periodontal status was accompanied by a reduction in both PSA levels and the incidence of urinary infections, suggesting a potential association between periodontal status and systemic health parameters. The correlation observed between periodontal probing depth and PSA levels, as well as between bleeding on probing and urinary infection rate, is compatible with a possible mechanistic link. Our results also align with studies identifying periodontal pathogens like P. gingivalis in prostate tissues, suggesting that microbial dissemination may contribute to genitourinary disease25. The observed reductions in inflammatory markers further support the hypothesis of an oral-genitourinary axis mediated by systemic inflammation. Despite these promising findings, several limitations must be acknowledged. The sample size was relatively small, which limits generalizability and statistical power for subgroup comparisons. The follow-up duration of 120 days may not be sufficient to assess the long-term impact of periodontal therapy on urological outcomes. In addition, no inflammatory biomarkers (e.g., CRP, IL-6) or microbial sequencing were performed to explore mechanistic pathways. Finally, although patients were randomized to treatment groups, factors such as hygiene adherence or past antibiotic exposure may have introduced residual confounding. Future studies should include larger, stratified populations with longer follow-up, as well as integration of immunological and microbiological analyses to better understand the systemic implications of periodontal inflammation. Additionally, the study did not distinguish between symptomatic urinary tract infections and asymptomatic bacteriuria, which may affect the clinical interpretation of the observed reductions in urine culture positivity. Additionally, the retrospective registration of the trial and the lack of blinding of participants and clinicians may have introduced bias. Baseline differences in PSA levels between groups further limit the internal validity of the findings. Therefore, results should be interpreted with caution. Conclusions Non-surgical periodontal therapy was associated with reductions in serum PSA levels and urine culture positivity, although these findings should be interpreted cautiously due to baseline imbalances. These findings suggest a potential association between periodontal inflammation and urogenital conditions; however, further large-scale studies are needed before clinical recommendations can be established. Electronic supplementary material Below is the link to the electronic supplementary material.Supplementary file 1. Supplementary file 1.